MiniMedTM 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage.

Socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), is associated with health disparities in diabetes management. This real-world analysis evaluated glycemic outcomes among United States users of the MiniMed™ 780G system, stratified by ADI percentile. Data from 40,975 users revealed consistent glycemic metrics across ADI groups, with a mean time in range (TIR) of 73%, time below range (TBR) of 1.3%, and time above range (TAR) of 25%, regardless of ADI grouping. Although statistically significant associations were observed between ADI and TBR, effect sizes were minimal and not clinically meaningful. Adoption of recommended optimal settings (ROS, an active insulin time of 2 h and a glucose target of 100 mg/dL, both for >95% of the time) significantly improved outcomes, with at least 68% of users achieving consensus-recommended glycemic targets compared to ∼50% in the overall analyzed population. These findings suggest the MiniMed™ 780G system delivers consistent glycemic outcomes across socioeconomic levels, offering a promising avenue for reducing diabetes-related health disparities.